|
【结 构 式】 
|
【分子编号】51471 【品名】methyl (1S,17R)-3-[[(7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methyl]sulfonyl]-17-(2-methoxyethyl)-3,13-diazapentacyclo[13.3.1.0(2,10).0(4,9).0(13,18)]nonadeca-2(10),4,6,8-tetraene-1-carboxylate 【CA登记号】 |
【 分 子 式 】C32H42N2O6S 【 分 子 量 】582.76136 【元素组成】C 65.95% H 7.26% N 4.81% O 16.47% S 5.5% |
与该中间体有关的原料药合成路线共 1 条
合成路线1
该中间体在本合成路线中的序号：(-)(+)-(II)The condensation of (rac?-18-methoxycoronaridine with (S)-(+)-camphorsulfonyl chloride (II) by means of KHMDS in THF gives the corresponding mixture of the diastereomeric sulfonamides (-)-(+)-(III) and (+)-(+)-(III), which are separated by normal phase silica gel chromatography. Both diastereomers are treated with KOH in methanol, yielding the target (-)- and (+)-enantiomers.
| 【1】 Herr, R.J.; Maisonneuve, I.M.; King, C.-H.R.; Meckler, H.; Glick, S.D.; Trova, M.P.; Synthesis of enantiomerically pure (+)- and (-)-18-methoxycoronaridine hydrochloride and their preliminary assessment as anti-addictive agents. Bioorg Med Chem Lett 2000, 10, 5, 473. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (+)-(II) | 18713 | (7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonyl chloride | C10H15ClO3S | 详情 | 详情 | |
| (-)(+)-(II) | 51471 | methyl (1S,17R)-3-[[(7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methyl]sulfonyl]-17-(2-methoxyethyl)-3,13-diazapentacyclo[13.3.1.0(2,10).0(4,9).0(13,18)]nonadeca-2(10),4,6,8-tetraene-1-carboxylate | C32H42N2O6S | 详情 | 详情 | |
| (+)(+)-(II) | 51472 | methyl (1R,17S)-3-[[(7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methyl]sulfonyl]-17-(2-methoxyethyl)-3,13-diazapentacyclo[13.3.1.0(2,10).0(4,9).0(13,18)]nonadeca-2(10),4,6,8-tetraene-1-carboxylate | C32H42N2O6S | 详情 | 详情 | |
| (I) | 51470 | methyl (1S,17R)-17-(2-methoxyethyl)-3,13-diazapentacyclo[13.3.1.0(2,10).0(4,9).0(13,18)]nonadeca-2(10),4,6,8-tetraene-1-carboxylate | C22H28N2O3 | 详情 | 详情 |
Extended Information